The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis

被引:39
|
作者
Liang, Chunlian [1 ]
Li, Xiuli [1 ]
Zhang, Lin [1 ]
Cui, Dajiang [1 ]
Quan, Xiaojuan [1 ]
Yang, Weilin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Geriatr, Sch Med, Xian 710004, Shaanxi, Peoples R China
关键词
miR-153; TGF-beta; TGFBR2; Idiopathic pulmonary fibrosis; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; LUNG FIBROSIS; EXTRACELLULAR-MATRIX; LATENT TGF-BETA-1; FIBROBLASTS; ACTIVATION; EXPRESSION; RECEPTORS; DIFFERENTIATION;
D O I
10.1016/j.yexmp.2015.07.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic lung disease with an undefined etiology and no effective treatments. By binding to cell surface receptors, transforming growth factor-beta (TGF-beta) plays a pivotal role in lung fibrosis. Therefore, the screening of microRNAs (miRNAs), especially those interrupting the effects of TGF-beta, may provide information not only on the pathomechanism, but also on the treatment of this disease. In the present study, we found that miR-153 expression was dysregulated in the lungs of mice with experimental pulmonary fibrosis and TGF-beta 1 decreased miR-153 expression in pulmonary fibroblasts. Moreover, increased miR-153 levels attenuated, whereas the knock down of miR-153 promoted the pro-fibrogenic activity of TGF-beta 1, and miR-153 reduced the contractile and migratory activities of fibroblasts. In addition, TGFBR2, a transmembrane serine/threonine kinase receptor for TGF-beta, was identified as a direct target of miR-153. Furthermore, by post-transcriptional regulation of the expression of TGEBR2, phosphorylation of SMAD2/3 was also influenced by miR-153. These data suggest that miR-153 disturbs TGF-beta 1 signal transduction and its effects on fibroblast activation, acting as an anti-fibrotic element in the development of pulmonary fibrosis. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 50 条
  • [31] Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Karakiulakis, George
    Tamm, Michael
    Lardinois, Didier
    Roth, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [32] Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats
    Amirkhosravi, Arian
    Goki, Maryamossadat Mirtajaddini
    Heidari, Mahmoud Reza
    Karami-Mohajeri, Somayyeh
    Iranpour, Maryam
    Torshabi, Maryam
    Mehrabani, Mitra
    Mandegary, Ali
    Mehrabani, Mehrnaz
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [33] Anti-fibrotic effects of Orostachys japonicus A. Berger (Crassulaceae) on hepatic stellate cells and thioacetamide-induced fibrosis in rats
    Koppula, Sushruta
    Yum, Mun-Jeong
    Kim, Jin-Seoub
    Shin, Gwang-Mo
    Chae, Yun-Jin
    Yoon, Tony
    Chun, Chi-Su
    Lee, Jae-Dong
    Song, MinDong
    NUTRITION RESEARCH AND PRACTICE, 2017, 11 (06) : 470 - 478
  • [34] ANTI-FIBROTIC AND ANTIOXIDANT AMELIORATIVE EFFECTS OF NARINGENIN AGAINST THIOACETAMIDE INDUCED LIVER FIBROSIS
    Ali, Haytham A.
    Afifi, Mohamed
    SLOVENIAN VETERINARY RESEARCH, 2023, 60 : 281 - 289
  • [35] The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
    Xi, Yue
    Li, Yanping
    Xu, Pengfei
    Li, Sihan
    Liu, Zhengsheng
    Tung, Hung-Chun
    Cai, Xinran
    Wang, Jingyuan
    Huang, Haozhe
    Wang, Menglin
    Xu, Meishu
    Ren, Songrong
    Li, Song
    Zhang, Min
    Lee, Yong J.
    Huang, Leaf
    Yang, Da
    He, Jinhan
    Huang, Zhiying
    Xie, Wen
    SCIENCE ADVANCES, 2021, 7 (36):
  • [36] SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis
    Tzouvelekis, Argyris
    Yu, Guoying
    Herazo-Maya, Jose
    Woolard, Tony
    Zhang, Yi
    Lee, Hojin
    Lee, Patty
    Herzog, Erica
    Bennett, Anton
    Kaminski, Naftali
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [37] Secretoglobin 3A2 Exhibits Anti-Fibrotic Activity in Bleomycin-Induced Pulmonary Fibrosis Model Mice
    Cai, Yan
    Kimura, Shioko
    PLOS ONE, 2015, 10 (11):
  • [38] TGF-β/Smad and JAK/STAT pathways are involved in the anti-fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis
    Xu, Shizan
    Mao, Yuqing
    Wu, Jianye
    Feng, Jiao
    Li, Jingjing
    Wu, Liwei
    Yu, Qiang
    Zhou, Yuting
    Zhang, Jie
    Chen, Jiaojiao
    Ji, Jie
    Chen, Kan
    Wang, Fan
    Dai, Weiqi
    Fan, Xiaoming
    Guo, Chuanyong
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (09) : 5224 - 5237
  • [39] Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
    Sara De Biasi
    Stefania Cerri
    Elena Bianchini
    Lara Gibellini
    Elisa Persiani
    Gloria Montanari
    Fabrizio Luppi
    Cristiano Matteo Carbonelli
    Luigi Zucchi
    Marialuisa Bocchino
    Alessandro Sanduzzi Zamparelli
    Carlo Vancheri
    Giacomo Sgalla
    Luca Richeldi
    Andrea Cossarizza
    BMC Medicine, 13
  • [40] Anti-fibrotic effects of lisinopril (ACE inhibitor) and fasudil (ROCK inhibitor) in combination for canine corneal fibrosis in vitro
    Routh, Brayden L.
    Tripathi, Ratnakar
    Giuliano, Elizabeth
    Lujin, Payton
    Sinha, Prashant R.
    Mohan, Rajiv R.
    VETERINARY OPHTHALMOLOGY, 2024,